entertainment -WSS

entertainment

author：focus 2025-08-23 04:59:13 - browse：1585

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Biotech venture capitalists face new demands from investors

knowledge

WSS

Texas Department of Public Safety speaks out on migrant abuse allegations

Driven by the pandemic, applicants flood public health schools

Stanford president's case begs question: Who takes blame?

Ending racial health disparities hinges on penalties, political will

Driven by the pandemic, applicants flood public health schools

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

hotspot

entertainment

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Vir antibody drug aimed at influenza A fails in clinical trial

Anesthesiologist group: stop taking Ozempic before surgery

EF3 tornado rips through North Carolina amid extreme weather nationwide

How one medical school became remarkably diverse

Test for long Covid? Researchers find new clue in blood samples

Dobbs anniversary: the lost opportunity of abortion as health care

AI generated plenty of interest at JPM but not a lot of trust

State Dept. review finds Biden bears some blame for Afghanistan failures

Awakening the world to the whoosh: A patient's crusade

Wikipedia

NIH director takes cautious approach to Biden drug pricing priority

7 more heat

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Texas Department of Public Safety speaks out on migrant abuse allegations

Why doctors need education on FDA device approval process

entertainment

knowledge

focus

focus